Aliqopa – Copanlisib Injection
Description
COPANLISIB (ALIQOPA) INJECTION – TREATMENT FOR LYMPHOMA
Aliqopa (copanlisib) is a cancer treatment that interferes with the development and spread of cancer cells in the body.
Aliqopa is used to treat follicular lymphoma that has relapsed after treatment with at least two different medications.
The US Food and Drug Administration (FDA) approved Aliqopa on the basis of “accelerated” development. Individuals with follicular lymphoma reacted to this drug in clinical trials. Nonetheless, additional testing is required.
Side Effects:
A new or worsening hack, chest agony, or discomfort relaxing; severe skin redness, tingling, or swelling; easy wounding, strange dying; disease manifestations – fever, chills, cold or influenza manifestations, mouth bruises, skin injuries;
High glucose – increased thirst, increased pee, hunger, cerebral pain, obscured vision, fruity breath smell; or high pulse – extreme cerebral pain, beating in your neck or ears, discombobulation, or feeling like you might pass out.
